Clinical Trial Detail

NCT ID NCT03737643
Title Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

fallopian tube cancer

peritoneum cancer

ovary serous adenocarcinoma

endometrioid ovary carcinoma

ovarian clear cell carcinoma

ovarian carcinosarcoma

Therapies

Bevacizumab + Carboplatin + Paclitaxel

Bevacizumab + Carboplatin + Durvalumab + Paclitaxel

Bevacizumab + Durvalumab + Olaparib

Olaparib

Bevacizumab + Durvalumab

Age Groups: senior adult

No variant requirements are available.